DiaSorin LIAISON® LymeDetect® The new paradigm in EARLY Lyme borreliosis detection DiaSorin strives to improve health-care around the globe through the development of innovative diagnostic solutions that can lead to better patient outcomes and provide economic benefits to the healthcare system. Thanks to its team of dedicated scientists, DiaSorin has developed a new concept assay to maximize EARLY Lyme borreliosis detection through a unique combination of humoral and cell mediated immunity. The unique diagnostic value of B cells combined with T cells LIAISON® LymeDetect® is an innovative approach to EARLY Lyme disease diagnostics that combines LIAISON® Borrelia IgG and IgM CLIA assays, with the patented QuantiFERON® IGRA technology. This potent combination ensures effective diagnosis of Lyme disease within weeks of contact with an infected tick, with concrete benefits for physicians, patients and laboratories. Faster detection means fewer health issues EARLY diagnosis of Lyme disease can identify and treat patients before severe illness develops. LIAISON® LymeDetect® has demonstrated a significant improvement in sensitivity vs standard two-tiered testing (sTTT) in the first 21 days of the infection, from 48.5% (sTTT) to 73.5% with LIAISON® LymeDetect®. Unlike cumbersome sTTT, LIAISON® LymeDetect® can respond to EARLY detection needs and reduce untreated infections that often lead to serious multi-organ complications. Streamlined EARLY Lyme borreliosis detection The fully automated and traceable workflow allows easy integration into daily lab routines and virtually eliminates the cumbersome hands-on and subjective reading of the current standard of care. Unlike manual processes, which introduce the likelihood of simple human error, LIAISON® LymeDetect® is a closed-loop system that ensures clear, reliable diagnostics for optimized workflows and better results. One clear diagnosis in one single step After loading the three reagent integrals on the LIAISON® XL or LIAISON® XS analyzer to automatically perform the CLIA assays, results are combined in a single qualitative assay. Giving you a clear diagnosis in as little as 24 hours. LIAISON® LymeDetect® is a powerful and cost-effective solution to increase diagnostic efficiency, optimize resources and limit chronic medical conditions. Easy, efficient and highly reliable With concrete performance in the EARLY detection of Lyme disease, LIAISON® LymeDetect® delivers diagnostic innovation you can rely on. Trademarks: QIAGEN®, Sample to Insight®, QFT®, QuantiFERON® (QIAGEN Group), LIAISON® (DiaSorin), LIAISON® LymeDetect® (DiaSorin). CLIA LIAISON® LymeDetect® HOME COMPANY CLINICAL AREAS Infectious Diseases Hepatitis and Retrovirus TORCH EBV MMRV Borrelia LymeDetect® Respiratory Infections Sepsis Tuberculosis Other Infectious Diseases Zika COVID-19 LIAISON® MeMed BV® Bone and Mineral Endocrinology Hypertension Oncology Stool Diagnostics Autoimmunity SYSTEMS COMMITTED TO EFFICIENCY NEWS EVENTS WORLDWIDE CONTACTS New Labeling & Packaging Download DiaSorin app for laboratories Diasorin Group Diasorin Molecular Luminex Corporation Legal Notices Privacy Policy Modern Slavery Act Statement DiaSorin S.p.A. - Share Capital € 55.948.257 R.E.A. 180729 Fiscal Code and Subscription to Vercelli Companies Register no 13144290155 English Italiano INTERNATIONAL USA Disclaimer: the DIASORIN site content linked here is for outside the United States only. Continue to our International Section Disclaimer: the DIASORIN site content linked here is for United States only. Continue to our US Section Ai sensi delle Linee Guida del Ministero della Salute del 28/03/2013, relative alla pubblicità sanitaria concernente i dispositivi medici, dispositivi medico-diagnostici in vitro e presidi medico-chirurgici, si avvisa l'utente che le informazioni contenute nel presente sito Internet e alle quali si sta per accedere sono esclusivamente rivolte agli operatori professionali Pursuant to the Guidelines of the Ministry of Health dated 28/03/2013 related to health advertising concerning medical devices, in vitro diagnostic medical devices and medical-surgical devices, we hereby inform you that the information contained in this website and to which you are going to access is exclusively intended for professional operators